Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Gains from Investment Securities (2021 - 2024)

Historic Gains from Investment Securities for Coeptis Therapeutics Holdings (COEP) over the last 3 years, with Q4 2024 value amounting to $539660.0.

  • Coeptis Therapeutics Holdings' Gains from Investment Securities changed N/A to $539660.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $539660.0, marking a year-over-year change of. This contributed to the annual value of $539660.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q4 2024, Coeptis Therapeutics Holdings' Gains from Investment Securities is $539660.0.
  • Coeptis Therapeutics Holdings' 5-year Gains from Investment Securities high stood at $16.8 million for Q4 2021, and its period low was -$14.2 million during Q1 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$150000.0 (2022), whereas its average is -$29930.9.
  • Data for Coeptis Therapeutics Holdings' Gains from Investment Securities shows a peak YoY increase of 9649.12% (in 2022) and a maximum YoY decrease of 13631.37% (in 2022) over the last 5 years.
  • Quarter analysis of 3 years shows Coeptis Therapeutics Holdings' Gains from Investment Securities stood at $16.8 million in 2021, then plummeted by 100.89% to -$150000.0 in 2022, then surged by 459.77% to $539660.0 in 2024.
  • Its Gains from Investment Securities stands at $539660.0 for Q4 2024, versus -$150000.0 for Q3 2022 and -$599176.0 for Q2 2022.